Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review
Canadian Respiratory Journal, 2018 Objectives. Although many studies have reported on the cost-effectiveness of bosentan for treating pulmonary arterial hypertension (PAH), a systematic review of economic evaluations of bosentan is currently lacking.
Ruxu You +7 more
doaj +2 more sources
Bosentan Reduces Myocardial Ischemia-Reperfusion Injury in Rats
Kardiyovasküler Tıp E Dergisi/E Journal of Cardiovascular MedicineObjectives: This study aimed to investigate the cardioprotective effects of bosentan, an endothelin receptor antagonist, against myocardial ischemia-reperfusion injury (MIRI) in rats.
Zeynep Yığman +6 more
doaj +2 more sources
Effect of bosentan therapy in persistent pulmonary hypertension of the newborn
Pediatrics and Neonatology, 2018 Background: Persistent pulmonary hypertension of the newborn (PPHN) contributes to neonatal hypoxemia and is associated with a high mortality. Some PPHN patients are unresponsive to inhaled nitric oxide (iNO).
Gunlawadee Maneenil +3 more
doaj +2 more sources
Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension
Annals of Hepatology, 2014 Background. Hepatotoxicity is a major side effect of treatment with bosentan in patients with pulmonary hypertension (PH). Bosentan is metabolized by the cytochrome CYP2C9 and inhibits the bile salt export pump, which is encoded by ABCB11.
Hans-Jürgen Seyfarth +9 more
doaj +2 more sources
Clinical Medicine Insights: Cardiology, 2013 This single-center, retrospective analysis evaluated long-term bosentan treatment in adult patients (n = 7) with both Down and Eisenmenger syndromes (DS-ES).
Giorgio Serino +7 more
doaj +2 more sources
An Atypical Presentation of Liver Enzyme Elevation Resulting from Bosentan Use
Canadian Respiratory Journal, 2009 Hepatocellular enzyme elevation is a known side effect of both bosentan and atorvastatin. However, a rise in liver enzyme level not characteristic of either agent individually may represent a reaction to their combination or an atypical reaction to ...
Kimberley Mulchey, Zoheir Bshouty
doaj +2 more sources
Trametinib Therapy for Hypertrophic Cardiomyopathy and Pulmonary Hypertension in a Child With RAF1-Related Noonan Syndrome (p.Ser257Leu): A Case Report. [PDF]
Clin Case RepABSTRACT This case describes a female infant with RAF1‐related Noonan syndrome who developed severe hypertrophic obstructive cardiomyopathy, pulmonary hypertension, and cardiorespiratory failure that responded to trametinib treatment but ultimately progressed to death following dose tapering and discontinuation of therapy. To the best of our knowledge,
Nilsson CN +8 more
europepmc +2 more sources
Use of Bosentan in neonatal post cardiac surgery pulmonary hypertension
Annals of Pediatric Cardiology, 2009 We report the use of Bosentan in the post-operative period of a neonate with obstructed infradiaphragmatic total anomalous pulmonary venous connection and severe pulmonary arterial hypertension.
Pawar Ravindra +3 more
doaj +1 more source
Portopulmonary hypertension practice patterns after liver transplantation
Liver Transplantation, EarlyView., 2022 Abstract Portopulmonary hypertension (POPH) is a type of pulmonary arterial hypertension occurring exclusively in those with portal hypertensive liver disease. Liver transplantation (LT) can significantly improve outcomes. Current guidelines counsel against immediate adjustments to targeted therapy after LT and suggest routine echocardiography as ...
Arun Jose +3 more
wiley +1 more source
CAQ Corner: Basic concepts of transplant immunology
, 2022 Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source